8189 — Tianjin TEDA Biomedical Engineering Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$924.06m
- HK$1.07bn
- CNY385.48m
Annual cashflow statement for Tianjin TEDA Biomedical Engineering Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -50 | -44.8 | -26.5 | -17.6 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 37.3 | 39.4 | 4.93 | 2.77 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 41.5 | -10.7 | -6.64 | -9.95 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 36 | -6.68 | -12.8 | -13.2 | — |
| Capital Expenditures | -6.12 | -27.6 | -8.8 | -2.47 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -20.4 | 19.1 | -4.13 | 2 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -26.5 | -8.51 | -12.9 | -0.467 | — |
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -20.2 | 28.1 | 6.17 | 12.7 | — |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.7 | 12.9 | -19.6 | -0.893 | — |